Therapeutics and Biomaterials for Musculoskeletal Disease: Global MarketsReport SummaryThe global market for musculoskelet...
REASONS FOR DOING THIS STUDYMusculoskeletal disease affects roughly 20% of the population and is a significantfactor in ov...
INFORMATION SOURCES     ANALYST CREDENTIALS     RELATED BCC REPORTS     BCC ONLINE SERVICES     DISCLAIMERCHAPTER TWO: SUM...
DISEASES OF THE SKELETAL MUSCLEMYOPATHYCHRONIC FATIGUE SYNDROMEFIBROMYALGIAMUSCULAR DYSTROPHYDERMATOMYOSITISPOLYMYOSITISRH...
New DevelopmentsNew TreatmentsRecent Clinical TrialsOutlook for Disease AreaGOUTEpidemiologySymptoms and DiagnosisStandard...
Recent Clinical TrialsOutlook for Disease AreaPSORIATIC ARTHRITISEpidemiologySymptoms and DiagnosisStandard of TreatmentNe...
CHAPTER FOUR: THERAPEUTICS     TABLE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 (%/$     MILLIONS)     FIGURE 3 GLOBAL...
CALCITONINS       TABLE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($ MILLIONS)       FIGURE 8 GLOBAL CALCITONINS MARKET FO...
VISCOSUPPLEMENTATION         TABLE 12 VISCOSUPPLEMENTATION MARKET SHARE BY PRODUCT, 2009 (%)         FIGURE 12 VISCOSUPPLE...
GROWTH OBSTACLESAPPLICATIONS     TABLE 16 GLOBAL PROJECTED MARKET FOR MSD, BY APPLICATION,     THROUGH 2014 ($ MILLIONS)  ...
BIOCOMPATIBILITY ISSUESEXISTING MARKETMEDTRONIC INFUSESTRYKER OP-1DEPUY MP52AVERAGE SELLING PRICEFUTURE OF THE MARKETTHERA...
REGULATORY CHALLENGESBIOSIMILARSCHAPTER SIX: RELATED DEALS AND PARTNERSHIPS     TABLE 27 VENTURE INVESTMENT IN MSD COMPANI...
CHAPTER NINE: COMPANY PROFILESAB SCIENCEABBOTTABLYNX, NVACCELERON PHARMAACTIVE BIOTECH RESEARCH ABALDER BIOPHARMACEUTICALS...
BONE MEDICAL, LTD.CAPSITONIN ORAL CALCITONINORAL PARATHYROID HORMONE BN003TNF REGULATORS BN006BONE CELL REGULATOR: BN005 A...
ESBATECHEUROFARMA LABSFERRING PHARMAFOREST LABSGENELABS TECHNOLOGIES (GSK)GENENTECH, INC.GENMAB A/SGENZYMEGLAXO WELLCOME U...
BONE VOID FILLINGCRANIOMAXILLOFACIAL SURGERYORAL AND PERIODONTAL REPAIRITALFARMACO S.P.A.JOHNSON & JOHNSONKENSEY NASHLEXIC...
NOVARTISNOVO NORDISK A/SNOXXON PHARMA AGNPS PHARMACEUTICALSNUON THERAPEUTICS, INC.NUVO RESEARCH, INC.NYCOMEDONO PHARMAORTH...
RADIUS HEALTHREGENERONRIGEL PHARMA, INC.RIVEX PHARMA, INC.ROCHESANOFI-AVENTISSERVIERSMITH & NEPHEW PLCSPINAL RESTORATION, ...
ZIMMERZOSANO PHARMAZYMOGENETICS, INC.ATACICEPT (FORMERLY TACI-IG)AUGMENT BONE GRAFT (FORMERLY GEMOS1TM)/AUGMENT INJECTABLE...
TABLE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 (%/$MILLIONS)TABLE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDINGBIOLO...
TABLE 17 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BYCOMPANY, 2009 (%)TABLE 18 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BYMATE...
LIST OF FIGURESSUMMARY FIGURE GLOBAL POTENTIAL MARKET FORMUSCULOSKELETAL DISEASE, 2009 AND 2014 ($ MILLIONS)FIGURE 1 PROPO...
FIGURE 10 VISCOSUPPLEMENTATION MARKET SHARE BYPRODUCT, 2009 (%)FIGURE 11 TOP 10 COMPANIES IN MSD MARKET BY GLOBALMARKET SH...
http://www.reportsnreports.comVisit our Market Research Blog
Upcoming SlideShare
Loading in...5
×

Therapeutics and biomaterials for musculoskeletal disease global markets

432

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
432
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Therapeutics and biomaterials for musculoskeletal disease global markets

  1. 1. Therapeutics and Biomaterials for Musculoskeletal Disease: Global MarketsReport SummaryThe global market for musculoskeletal disease is currently approaching $45 billion.The overall 5-year compound annual growth rate (CAGR) is forecasted to be about5%, bringing the total market to more than $57 billion by 2014.Rheumatoid arthritis and osteoarthritis currently represent 53% of the total market.The RA market was worth an estimated $9.5 billion in 2009 and should reach nearly$12.5 billion by 2015, while the osteoarthritis segment was valued at $14.5 billionin 2009 and should reach an estimated $19 billion by 2014. For both sectors thisrepresents a compound annual growth rate (CAGR) of 5.6%.Lupus is an emerging area for development, as outcome measures andunderstanding of the disease pathology become more refined. This segment wasvalued at $1.5 billion in 2009 and is projected to reach $2 billion by 2014, acompound annual growth rate (CAGR) of 5.2%.INTRODUCTIONSTUDY GOALS AND OBJECTIVESBCC’s goal in conducting this study was to determine the current status of themusculoskeletal disease (MSD) treatments and assess the growth potential of thisarea over a 5-year period from 2009 to 2014.Our key objective was to present a comprehensive analysis of the current pipelineof therapeutics and biomaterials utilized in the treatment of MSDs, analyze theforecast for Musculoskeletal Disease Therapeutics Market and treatments, andoutline the key factors that will influence this therapeutic area in the next fewyears.Diseases of the musculoskeletal system have plagued a significant portion of thepopulation, and the number of incidence increases as the population ages. Therehave been many successful therapeutics marketed to date, but there is still roomfor more effective therapies. Advances in biomaterials are being translated intoviable products in the orthobiologics area as well, thus changing the way a numberof related disease states are treated. More is being elucidated about these diseases,and this promises to translate into more therapies and market opportunities for avariety of players.Browse All Pharmaceuticals Market Research
  2. 2. REASONS FOR DOING THIS STUDYMusculoskeletal disease affects roughly 20% of the population and is a significantfactor in overall healthcare expenditure. Diseases such as rheumatoid arthritis,osteoporosis, and osteoarthritis are treated with various drug types, and a largedevelopment pipeline of potential new therapies is currently being tested. Clinicalsuccess has proven elusive, however, as there are now numerous companiesdeveloping novel treatments. This report reviews the programs in development andquantifies the market opportunities in MSDs. This study aims to quantify thedirection in which this market is heading and the areas in which opportunities maylie.SCOPE OF REPORTThe scope of this report focuses on the ethical pharmaceutical segment andbiomaterials areas, usually categorized with medical devices. We have compiled astudy of the market, as well as current and emerging modes of treatment. Wepresent the segment economic environment, technological descriptions and issues,applications, market factors and potential, and forecasts for the time period from2009 to 2014. We also project usage in the major primary and secondary diseaseapplication areas. This study will be of interest to the drug industry, patients, andthe medical community. It will also be of interest also to suppliers of products andservices to this market area.INTENDED AUDIENCEThe intended audience for this report is the pharmaceutical and biotechnologydiagnostics industries, as well as the medical industry that treats patients in theseareas.METHODOLOGYBCC presents an analysis by each disease area and the number of current patients.Based on our surveys, we then analyze the potential applications forpharmaceuticals and forecast markets for 2009 and 2014.Table of ContentsCHAPTER ONE: INTRODUCTION STUDY GOALS AND OBJECTIVES REASONS FOR DOING THIS STUDY SCOPE OF REPORT INTENDED AUDIENCE METHODOLOGY
  3. 3. INFORMATION SOURCES ANALYST CREDENTIALS RELATED BCC REPORTS BCC ONLINE SERVICES DISCLAIMERCHAPTER TWO: SUMMARY SUMMARY SUMMARY TABLE GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, THROUGH 2014 ($ MILLIONS) FIGURE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, 2009 AND 2014 ($ MILLIONS)CHAPTER THREE: OVERVIEWTABLE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONIC MEDICALCONDITIONS (%)FIGURE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONIC MEDICALCONDITIONS (%)DEFINITION AND MARKET STRUCTURETABLE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE,THROUGH 2014 ($ MILLIONS)FIGURE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETAL DISEASE, 2009AND 2014 ($ MILLIONS)DISEASES OF THE BONEOSTEOPOROSISPAGET’S DISEASEOSTEOMALACIARICKETSOSTEOMYELITISAVASCULAR NECROSIS (OSTEONECROSIS)
  4. 4. DISEASES OF THE SKELETAL MUSCLEMYOPATHYCHRONIC FATIGUE SYNDROMEFIBROMYALGIAMUSCULAR DYSTROPHYDERMATOMYOSITISPOLYMYOSITISRHABDOMYOLYSISCOMPARTMENT SYNDROMEDISEASES OF THE JOINTSRHEUMATOID ARTHRITIS (RA)EpidemiologySymptoms and DiagnosisStandard of TreatmentNew DevelopmentsNew TreatmentsRecent Clinical TrialsOutlook for Disease AreaLUPUSCausesEpidemiologySymptoms and DiagnosisStandard of Treatment
  5. 5. New DevelopmentsNew TreatmentsRecent Clinical TrialsOutlook for Disease AreaGOUTEpidemiologySymptoms and DiagnosisStandard of TreatmentNew TreatmentsRecent Clinical TrialsOutlook for Disease AreaJUVENILE IDIOPATHIC ARTHRITISEpidemiologySymptoms and DiagnosisStandard of TreatmentNew TreatmentsRecent Clinical TrialsOutlook for Disease AreaOSTEOARTHRITISEpidemiologySymptoms and DiagnosisStandard of TreatmentNew Treatments
  6. 6. Recent Clinical TrialsOutlook for Disease AreaPSORIATIC ARTHRITISEpidemiologySymptoms and DiagnosisStandard of TreatmentNew TreatmentsRecent Clinical TrialsOutlook for Disease AreaANKYLOSING SPONDYLITISEpidemiologySymptoms and DiagnosisStandard of TreatmentRecent Clinical TrialsOutlook for Disease AreaOSTEOPOROSISEpidemiologySymptoms and DiagnosisStandard of TreatmentNew TreatmentsRecent Clinical TrialsOutlook for Disease Area
  7. 7. CHAPTER FOUR: THERAPEUTICS TABLE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 (%/$ MILLIONS) FIGURE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 ($ MILLIONS)DMARDS TABLE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDING BIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONS) FIGURE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDING BIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONSBIOLOGICSNSAIDS TABLE 5 GLOBAL REVENUE OF NSAIDS FOR MSD, 2009 ($ MILLIONS) FIGURE 5 GLOBAL REVENUE OF NSAIDS FOR MSD BY DRUG, 2009 ($ MILLIONS)CORTICOSTEROIDS TABLE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009 ($ MILLIONS) FIGURE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009 ($ MILLIONS)BISPHOSPHONATES TABLE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($ MILLIONS) FIGURE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($ MILLIONS)
  8. 8. CALCITONINS TABLE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($ MILLIONS) FIGURE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($ MILLIONS)ESTROGEN REPLACEMENT THERAPYSELECTIVE ESTROGEN RECEPTOR MODULATORS TABLE 9 GLOBAL SERM MARKET FOR MSD, 2009 ($ MILLIONS)PARATHYROID HORMONE TABLE 10 GLOBAL PTH MARKET FOR MSD ($ MILLIONS)ORTHOBIOLOGICSBMPS TABLE 11 GLOBAL BMP MARKET FOR MSD, 2009 ($ MILLIONS) FIGURE 9 GLOBAL BMP MARKET FOR MSD BY COMPANY, 2009 ($ MILLIONS)PROTEIN THERAPYGENE THERAPYCELLULAR THERAPYSYNTHETIC BONE GRAFTPOLYMERSCOMPOSITE GRAFTSDEMINERALIZED BONE MATRIX
  9. 9. VISCOSUPPLEMENTATION TABLE 12 VISCOSUPPLEMENTATION MARKET SHARE BY PRODUCT, 2009 (%) FIGURE 12 VISCOSUPPLEMENTATION MARKET SHARE BY PRODUCT, 2009 (%)MARKET SIZE AND KEY PLAYERS TABLE 13 TOP 10 COMPANIES IN MSD MARKET, REVENUE AND ASSOCIATED GLOBAL MARKET SHARE, 2009 ($ MILLIONS/%) FIGURE 13 TOP 10 COMPANIES IN MSD MARKET BY GLOBAL MARKET SHARE, 2009 (%)MARKET SIZEKEY PLAYERSPfizerAbbottJ&JMerckAmgenRocheUCBBMSMedtronicGLOBAL INDUSTRY STRUCTURE TABLE 14 SWOT ANALYSIS OF MSD MARKET: NSAIDS TABLE 15 SWOT ANALYSIS OF MSD MARKET: BIOLOGICALSGROWTH DRIVERS
  10. 10. GROWTH OBSTACLESAPPLICATIONS TABLE 16 GLOBAL PROJECTED MARKET FOR MSD, BY APPLICATION, THROUGH 2014 ($ MILLIONS) FIGURE 12 GLOBAL PROJECTED MARKET FOR MSD, BY APPLICATION, 2006- 2014 ($ MILLIONS)ORTHOBIOLOGICS TABLE 17 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BY COMPANY, 2009 (%) FIGURE 15 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BY COMPANY, 2009 (%)AUTOGENOUS BONE GRAFT AND THE BONE GRAFT SUBSTITUTE MARKETFUSION RATES: ALWAYS ROOM FOR IMPROVEMENTDRIVERS OF GROWTH IN THE MARKETSEGMENTS IN THE BONE AND BONE SUBSTITUTE MARKETFUTURE DISPLACEMENT IN A DYNAMIC SPINE MARKET? TABLE 18 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BY MATERIAL TYPE, THROUGH 2014 ($ MILLIONS) FIGURE 16 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BY MATERIAL TYPE, 2008-2014 ($ MILLIONS)MARKET CHALLENGESHIGH COST OF BMPSPATENT PROTECTION
  11. 11. BIOCOMPATIBILITY ISSUESEXISTING MARKETMEDTRONIC INFUSESTRYKER OP-1DEPUY MP52AVERAGE SELLING PRICEFUTURE OF THE MARKETTHERAPEUTICS TABLE 19 PROJECTED MARKET FOR KEY MSD PRODUCTS, THROUGH 2014 ($ MILLIONS) FIGURE 15 PROJECTED MARKET FOR KEY MSD PRODUCTS, 2008-2014 ($MILLIONS) TABLE 20 TREATMENTS AND MOASUMMARY OF COMMON MEDICATIONS TABLE 21 SIDE EFFECTS TABLE 22 PREVALENCE OF MAJOR MSDS IN MAJOR GLOBAL MARKETS, 2009 (%) TABLE 23 GLOBAL POTENTIAL MARKET FOR TOTAL MSD, THROUGH 2014 ($ MILLIONS) TABLE 24 KEY OTC TREATMENTS AND NATURAL PRODUCTS TABLE 25 DRUGS USED TO TREAT MSD TABLE 26 LEADING MSD THERAPIES AND COST PER DAY (U.S. DOLLARS)CHAPTER FIVE: LEGISLATION AND REGULATORY ENVIRONMENTHEALTHCARE REFORMCOST-BENEFIT ANALYSISREIMBURSEMENT AND PRICING
  12. 12. REGULATORY CHALLENGESBIOSIMILARSCHAPTER SIX: RELATED DEALS AND PARTNERSHIPS TABLE 27 VENTURE INVESTMENT IN MSD COMPANIESRELATED DEALS AND … TABLE 28 RELATED DEALS AND PARTNERSHIPSCHAPTER SEVEN: PIPELINE TABLE 29 CLINICAL DEVELOPMENT PIPELINECHAPTER EIGHT: PATENT ANALYSISPATENT EXPIRATIONSACTEMRASIMPONIKINERETCIMZIANEW PATENTS FILED TABLE 30 PATENT ANALYSIS TABLE 31 KEY PATENT HOLDERS IN BONE/JOINT DISEASE AREA (NUMBER/%) FIGURE 19 KEY PATENT HOLDERS IN BONE/JOINT DISEASE MARKET (%)
  13. 13. CHAPTER NINE: COMPANY PROFILESAB SCIENCEABBOTTABLYNX, NVACCELERON PHARMAACTIVE BIOTECH RESEARCH ABALDER BIOPHARMACEUTICALS, INC.ALETHIA BIOTHERAPEUTICS, INC.AMGENARANA THERAPEUTICSARRAY BIOPHARMAASTELLASASTION PHARMA A/SASTRAZENECABAYER SCHERING PHARMA AGBIOGENIDECBIOIBERICABIOMETBIOTIE THERAPIESBMSBOEHRINGER INGELHEIM
  14. 14. BONE MEDICAL, LTD.CAPSITONIN ORAL CALCITONINORAL PARATHYROID HORMONE BN003TNF REGULATORS BN006BONE CELL REGULATOR: BN005 AND BN008BTG INTERNATIONAL LTD.CAN-FITE BIOPHARMACARTICEPT MEDICAL, INC.CELGENE CORPORATIONCENTOCOR ORTHO BIOTECHCEPHALON, INC.CHELSEA THERAPEUTICS, INC.CHEMOCENTRYX, INC.CHUGAI TABLE 32 CHUGAI H’S PROGRAMS IN DEVELOPMENT FOR BONE AND JOINT DISEASESCOMBINATORX, INC.CRYSTAL GENOMICSCYTOKINETICSDELENEX THERAPEUTICS AGELANELI LILLY
  15. 15. ESBATECHEUROFARMA LABSFERRING PHARMAFOREST LABSGENELABS TECHNOLOGIES (GSK)GENENTECH, INC.GENMAB A/SGENZYMEGLAXO WELLCOME U.K., LTD. (GSK)HALOZYME THERAPEUTICSHARBOR BIOSCIENCES, INC. (FORMERLY HOLLIS-EDEN)HORIZON THERAPEUTICSHUMAN GENOME SCIENCESHUMANIS KLINIKUMIDERA PHARMACEUTICALSIMMUNOMEDICS, INC.IMMUPHARMA, PLCINCYTEIPSENISOTIS ORTHOBIOLOGICS (ACQUIRED BY INTEGRA LIFESCIENCES)SPINAL FUSIONTRAUMAJOINT REVISION
  16. 16. BONE VOID FILLINGCRANIOMAXILLOFACIAL SURGERYORAL AND PERIODONTAL REPAIRITALFARMACO S.P.A.JOHNSON & JOHNSONKENSEY NASHLEXICON PHARMACEUTICALSMEDAREXMEDIGENE AGMEDIMMUNE, LLCMEDIPOST CO., LTD.MEDIVIR ABMIV 710/711 (CATH-K)MEDTRONIC SOFAMOR DANEKMERCKMERRIMACK PHARMACEUTICALSMERRION PHARMACEUTICALS, LTD.MITSUBISHI TANABEMORPHOSYS AGNEOVACS SANICOX SANIPPON KAYAKUNORDIC BIOSCIENCE A/S
  17. 17. NOVARTISNOVO NORDISK A/SNOXXON PHARMA AGNPS PHARMACEUTICALSNUON THERAPEUTICS, INC.NUVO RESEARCH, INC.NYCOMEDONO PHARMAORTHOVITAOSTEOLOGIX, INC.OSTEOTECHPALAU PHARMAPANGENETICS BVPG102-PROTOTYPEPG102PASCOE PHARMAPDL BIOPHARMA, INC.PFIZERPHYTOHEALTH CORPORATIONPHN031(PH3)DescriptionDevelopment StatusPOZEN, INC.
  18. 18. RADIUS HEALTHREGENERONRIGEL PHARMA, INC.RIVEX PHARMA, INC.ROCHESANOFI-AVENTISSERVIERSMITH & NEPHEW PLCSPINAL RESTORATION, INC.STRYKER BIOTECHSUCAMPO PHARMACEUTICALS, INC.SYNTHES, INC.TAKEDATEVATRUBION PHARMACEUTICALS INC.TRUBION PHARMACEUTICALS INC. (CONTINUED)UCBUNIGENE LABSVERTO MEDICAL, LTD.WRIGHT MEDICAL TECHNOLOGY INC.XOMAZELOS THERAPEUTICS, INC.ZELOS THERAPEUTICS, INC. (CONTINUED)
  19. 19. ZIMMERZOSANO PHARMAZYMOGENETICS, INC.ATACICEPT (FORMERLY TACI-IG)AUGMENT BONE GRAFT (FORMERLY GEMOS1TM)/AUGMENT INJECTABLE BONEGRAFT (FORMERLY GEM-OS2TM)CHAPTER TEN: OUTLOOK—TRENDS AND CHALLENGESMSDS ARE A LARGE BURDEN ON THE HEALTHCARE SYSTEMOUTLOOK FOR ORTHOBIOLOGICS IS BRIGHTOSTEOPOROSIS: PAYER ACCEPTANCE IS KEY ISSUECOMPETITION FOR THE RA PATIENT POPULATION FAILING ANTI-TNF THERAPIESLUPUS IS A CHALLENGING INDICATIONDIAGNOSIS RATES FOR PSORIATIC ARTHRITIS AND ASLIST OF TABLESSUMMARY TABLE GLOBAL POTENTIAL MARKET FORMUSCULOSKELETAL DISEASE, THROUGH 2014 ($ MILLIONS)TABLE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONICMEDICAL CONDITIONS (%)TABLE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETALDISEASE, THROUGH 2014 ($ MILLIONS)
  20. 20. TABLE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 (%/$MILLIONS)TABLE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDINGBIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONS)TABLE 5 GLOBAL REVENUE OF NSAIDS FOR MSD, 2009 ($ MILLIONS)TABLE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009($ MILLIONS)TABLE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($MILLIONS)TABLE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($MILLIONS)TABLE 9 GLOBAL SERM MARKET FOR MSD, 2009 ($ MILLIONS)TABLE 10 GLOBAL PTH MARKET FOR MSD ($ MILLIONS)TABLE 11 GLOBAL BMP MARKET FOR MSD, 2009 ($MILLIONS)TABLE 12 VISCOSUPPLEMENTATION MARKET SHARE BYPRODUCT, 2009 (%)TABLE 13 TOP 10 COMPANIES IN MSD MARKET, REVENUE ANDASSOCIATED GLOBAL MARKET SHARE, 2009 ($ MILLIONS/%)TABLE 14 SWOT ANALYSIS OF MSD MARKET: NSAIDSTABLE 15 SWOT ANALYSIS OF MSD MARKET: BIOLOGICALSTABLE 16 GLOBAL PROJECTED MARKET FOR MSD, BYAPPLICATION, THROUGH 2014 ($ MILLIONS)
  21. 21. TABLE 17 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BYCOMPANY, 2009 (%)TABLE 18 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BYMATERIAL TYPE, THROUGH 2014 ($ MILLIONS)TABLE 19 PROJECTED MARKET FOR KEY MSD PRODUCTS,THROUGH 2014 ($ MILLIONS)TABLE 20 TREATMENTS AND MOATABLE 21 SIDE EFFECTSTABLE 22 PREVALENCE OF MAJOR MSDS IN MAJOR GLOBALMARKETS, 2009 (%)TABLE 23 GLOBAL POTENTIAL MARKET FOR TOTAL MSD, THROUGH2014 ($ MILLIONS)TABLE 24 KEY OTC TREATMENTS AND NATURAL PRODUCTSTABLE 25 DRUGS USED TO TREAT MSDTABLE 26 LEADING MSD THERAPIES AND COST PER DAY (U.S.DOLLARS)TABLE 27 VENTURE INVESTMENT IN MSD COMPANIESTABLE 28 RELATED DEALS AND PARTNERSHIPSTABLE 29 CLINICAL DEVELOPMENT PIPELINETABLE 30 PATENT ANALYSISTABLE 31 KEY PATENT HOLDERS IN BONE/JOINT DISEASE AREA(NUMBER/%)TABLE 32 CHUGAI H’S PROGRAMS IN DEVELOPMENT FOR BONEAND JOINT DISEASES
  22. 22. LIST OF FIGURESSUMMARY FIGURE GLOBAL POTENTIAL MARKET FORMUSCULOSKELETAL DISEASE, 2009 AND 2014 ($ MILLIONS)FIGURE 1 PROPORTION OF U.S. POPULATION REPORTING CHRONICMEDICAL CONDITIONS (%)FIGURE 2 GLOBAL POTENTIAL MARKET FOR MUSCULOSKELETALDISEASE, 2009 AND 2014 ($ MILLIONS)FIGURE 3 GLOBAL REVENUE OF THERAPEUTICS FOR MSD, 2009 ($MILLIONS)FIGURE 4 GLOBAL REVENUE OF DMARDS FOR MSD, INCLUDINGBIOLOGICAL RESPONSE MODIFIERS, BY DRUG, 2009 ($ MILLIONSFIGURE 5 GLOBAL REVENUE OF NSAIDS FOR MSD BY DRUG, 2009 ($MILLIONS)FIGURE 6 GLOBAL REVENUES OF CORTICOSTEROIDS FOR MSD, 2009($ MILLIONS)FIGURE 7 GLOBAL BISPHOSPHONATES MARKET FOR MSD, 2009 ($MILLIONS)FIGURE 8 GLOBAL CALCITONINS MARKET FOR MSD, 2009 ($MILLIONS)FIGURE 9 GLOBAL BMP MARKET FOR MSD BY COMPANY, 2009 ($MILLIONS)
  23. 23. FIGURE 10 VISCOSUPPLEMENTATION MARKET SHARE BYPRODUCT, 2009 (%)FIGURE 11 TOP 10 COMPANIES IN MSD MARKET BY GLOBALMARKET SHARE, 2009 (%)FIGURE 12 GLOBAL PROJECTED MARKET FOR MSD, BYAPPLICATION, 2006-2014 ($ MILLIONS)FIGURE 13 GLOBAL ORTHOBIOLOGICS MARKET SHARE, BYCOMPANY, 2009 (%)FIGURE 14 GLOBAL MARKET FORECAST FOR ORTHOBIOLOGICS, BYMATERIAL TYPE, 2008-2014 ($ MILLIONS)FIGURE 15 PROJECTED MARKET FOR KEY MSD PRODUCTS, 2008-2014 ($MILLIONS)FIGURE 16 KEY PATENT HOLDERS IN BONE/JOINT DISEASEMARKET (%)About Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.com
  24. 24. http://www.reportsnreports.comVisit our Market Research Blog

×